SCHEMBL851124

SCHEMBL851124

N#Cc1ccc(Oc2ccc(NS(=O)(=O)c3ccc4ccccc4c3)c(Oc3ccc(C#N)cc3)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
CACNA1H O95180 1/20 0.53
CACNA1B Q00975 1/20 0.53
KAT6A Q92794 1/20 0.49
STAT3 P40763 1/20 0.47
ACLY P53396 1/20 0.47
PLA2G7 Q13093 3/20 0.46
KDM4E B2RXH2 1/20 0.46
PRSS1 P07477 2/20 0.45
PRSS2 P07478 2/20 0.45
PRSS3 P35030 2/20 0.45
ST14 Q9Y5Y6 2/20 0.45
F2 P00734 1/20 0.45
F10 P00742 1/20 0.45
SLC22A12 Q96S37 1/20 0.45
CKS1B P61024 1/20 0.45
SKP2 Q13309 1/20 0.45
SLC16A3 O15427 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL851450 0.84 SLC22A12 (0.54) PGRMEN1KMT2ACACNA1HCACNA1B
SCHEMBL852159 0.82 PRSS1 (0.65) PGRMEN1KMT2ACACNA1HCACNA1B
SCHEMBL850766 0.82 PGR (0.54) PGRCACNA1HCACNA1BACLYSLC22A12
SCHEMBL850942 0.81 ST14 (0.68) PGRMEN1KMT2ACACNA1HCACNA1B
SCHEMBL851549 0.80 ST14 (0.71) PGRMEN1KMT2APLA2G7PRSS1
SCHEMBL12230253 0.78 ATM (0.67) PGRMEN1KMT2AKAT6AKDM4E
SCHEMBL851703 0.76 MRGPRX1 (0.52) PGRMEN1KMT2APLA2G7PRSS1
SCHEMBL7572129 0.76 GLO1 (0.60) KAT6ASTAT3ACLYKDM4ESLC22A12
SCHEMBL28316252 0.75 LMNA (0.69) PGRMEN1KMT2APLA2G7KDM4E
SCHEMBL921076 0.74 CYP19A1 (0.50) MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722930-B2 Protease inhibitors ORION CORPORATION (FI) 2014-05-13 US disclosed
US-20120136002-A1 PROTEASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-05-31 US disclosed
EP-2432556-A1 PROTEASE INHIBITORS Orion Corporation (FI) 2012-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136002-A1 PROTEASE INHIBITORS SERPINB1, TMPRSS15, PRSS1 PGR 354/4885MEN1 258/4885KMT2A 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.